Minor Proteins Involved in Neuronal Functions in Serum of Patients With Major Mental Disorders According to Proteomic Analysis
7 affiliations
- 1Laboratory of Molecular Psychiatry, Mental Health Research Institute, Tomsk National Research Medical Center of the Russian Academy of Sciences, 634014 Tomsk, Russia
- 2Laboratory of Repair Enzymes, Institute of Chemical Biology and Fundamental Medicine, Siberian Branch of the Russian Academy of Sciences, 630090 Novosibirsk, Russia
- 3Advanced Mass Spectrometry Core Facility, Skolkovo Institute of Science and Technology, 121205 Moscow, Russia
- 4Laboratory of Systems Biology, Institute of Biomedical Chemistry, 119121 Moscow, Russia
- 5Affective States Department, Mental Health Research Institute, Tomsk National Research Medical Center of the Russian Academy of Sciences, 634014 Tomsk, Russia
- 6Endogenous Disorders Department, Mental Health Research Institute, Tomsk National Research Medical Center of the Russian Academy of Sciences, 634014 Tomsk, Russia
- 7Psychiatry, Addictology and Psychotherapy Department, Siberian State Medical University, 634050 Tomsk, Russia
Abstract
Background:: Schizophrenia (SCZ) and bipolar disorder (BD) share common clinical features, complicating the identification of specific peripheral biomarkers. The objective of this study was to identify biomarkers that specifically characterize different clinical forms of BD and SCZ.
Methods:: A comparative proteomic analysis of serum samples from patients with SCZ and BD, as well as healthy controls, was performed using untargeted mass spectrometry to identify differentially expressed proteins. In an expanded cohort, accounting for clinical heterogeneity, the levels of six minor proteins (N-methyl-D-aspartate receptor 1 (NMDAR1), ankyrin 3 (ANK3), ankyrin repeat domain-containing protein 12 (ANKRD12), low-density lipoprotein receptor-related protein 2 (LRP2), dermcidin (DCD), and anti-NMDAR antibodies) were quantified using enzyme-linked immunosorbent assay (ELISA) and targeted mass spectrometry (for NMDAR1).
Results:: Comparative serum proteomic analysis identified 440 unique proteins in healthy controls versus 221 in patients with SCZ, and 474 unique proteins in healthy controls versus 55 in patients with BD. Quantitative analysis revealed the following findings: (1) a significant increase in NMDAR1 protein levels in patients with BD experiencing a current depressive episode (BD-cDE); (2) decreased ANK3 levels in patients with BD-cDE and SCZ; (3) increased ANKRD12 protein levels in patients with SCZ characterized by predominant negative symptoms and in patients with BD-cDE; (4) decreased DCD levels in patients with SCZ in remission compared with those in the acute phase of the disease; and (5) significantly increased LRP2 levels in both BD and SCZ. Elevated anti-NMDAR antibody levels were more frequently observed in patients with BD, although absolute antibody levels were also increased in patients with acute-phase SCZ.
Conclusions:: These findings suggest a common mechanism of synaptopathy involving destabilization of the ANK3-NMDAR scaffold, accompanied by a compensatory neuroprotective response in both BD and SCZ. The identified alterations in the serum protein profile may serve as potential biomarkers for the differential diagnosis of these disorders as part of multimarker diagnostic panels.
Related
- Psychosocial profile of adults with Congenital Heart Disease according to documented history of anxiety disorders
- Risk of atrial fibrillation according to electrocardiographic risk factors: a nationwide cohort study of 1.5 million patients
- Cerebral Hemodynamic Changes in Older Adults With Cognitive Complaints According to the Presence of Peripheral Artery Disease
- Machine learning-guided screening of urine cultures for urinary tract infection diagnosis according to AMCLI guidelines
- Prognostic Impact of Transient Return of Spontaneous Circulation According to Low-Flow Time in Patients with Out-of-Hospital Cardiac Arrest Undergoing Extracorporeal Cardiopulmonary Resuscitation: A Nationwide Cohort Study
BibTeX
@article{smirnova2026minor,
title = {{Minor Proteins Involved in Neuronal Functions in Serum of Patients With Major Mental Disorders According to Proteomic Analysis}},
author = {Liudmila Smirnova and Alexander Seregin and Evgeny Ermakov and Maria Zavialova and Elena Dmitrieva and Svetlana Novikova and German Simutkin and Elena Kornetova and Svetlana Ivanova},
journal = {Alpha Psychiatry},
year = {2026},
month = oct,
doi = {10.31083/ap53136},
url = {https://doi.org/10.31083/ap53136},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Minor Proteins Involved in Neuronal Functions in Serum of Patients With Major Mental Disorders According to Proteomic Analysis
AU - Liudmila Smirnova
AU - Alexander Seregin
AU - Evgeny Ermakov
AU - Maria Zavialova
AU - Elena Dmitrieva
AU - Svetlana Novikova
AU - German Simutkin
AU - Elena Kornetova
AU - Svetlana Ivanova
PY - 2026
DA - 2026/10/23
JO - Alpha Psychiatry
DO - 10.31083/ap53136
UR - https://doi.org/10.31083/ap53136
AB - Background:: Schizophrenia (SCZ) and bipolar disorder (BD) share common clinical features, complicating the identification of specific peripheral biomarkers. The objective of this study was to identify biomarkers that specifically characterize different clinical forms of BD and SCZ. Methods:: A comparative proteomic analysis of serum samples from patients with SCZ and BD, as well as healthy controls, was performed using untargeted mass spectrometry to identify differentially expressed proteins. In an expanded cohort, accounting for clinical heterogeneity, the levels of six minor proteins (N-methyl-D-aspartate receptor 1 (NMDAR1), ankyrin 3 (ANK3), ankyrin repeat domain-containing protein 12 (ANKRD12), low-density lipoprotein receptor-related protein 2 (LRP2), dermcidin (DCD), and anti-NMDAR antibodies) were quantified using enzyme-linked immunosorbent assay (ELISA) and targeted mass spectrometry (for NMDAR1). Results:: Comparative serum proteomic analysis identified 440 unique proteins in healthy controls versus 221 in patients with SCZ, and 474 unique proteins in healthy controls versus 55 in patients with BD. Quantitative analysis revealed the following findings: (1) a significant increase in NMDAR1 protein levels in patients with BD experiencing a current depressive episode (BD-cDE); (2) decreased ANK3 levels in patients with BD-cDE and SCZ; (3) increased ANKRD12 protein levels in patients with SCZ characterized by predominant negative symptoms and in patients with BD-cDE; (4) decreased DCD levels in patients with SCZ in remission compared with those in the acute phase of the disease; and (5) significantly increased LRP2 levels in both BD and SCZ. Elevated anti-NMDAR antibody levels were more frequently observed in patients with BD, although absolute antibody levels were also increased in patients with acute-phase SCZ. Conclusions:: These findings suggest a common mechanism of synaptopathy involving destabilization of the ANK3-NMDAR scaffold, accompanied by a compensatory neuroprotective response in both BD and SCZ. The identified alterations in the serum protein profile may serve as potential biomarkers for the differential diagnosis of these disorders as part of multimarker diagnostic panels.
SN - 2757-8038
ER -